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Abstract: Since major meta-analyses of randomized controlled trials in interventional 
cardiology showed the potential of drug-eluting stents in decreasing restenosis and reintervention 
rates after coronary artery stenting, one of the next steps in the treatment of arterial occlusive 
disease is the transfer of the active coating technology towards peripheral arterial interventions. 
In this manuscript, we aim to provide a literature overview on available peripheral (lower limb, 
renal, and supra-aortic) drug-eluting stent applications, debate the cost implications, and give 
recommendations for future treatment strategies.
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Endovascular interventional techniques have been used to treat peripheral arterial 
occlusive disease (PAOD) since their conception and, despite many improvements, they 
remain the subject of continued modiﬁ  cations. Although percutaneous transluminal 
angioplasty (PTA) and stenting are now widely accepted and are even gradually replac-
ing traditional open peripheral vascular surgical approaches, there remains one sig-
niﬁ  cant limiting factor: post-angioplasty and in-stent restenosis. Major meta-analyses 
of randomized controlled trials (RCT) from interventional cardiology show that in 
coronary artery disease, the use of drug-eluting stents (DES) has resulted in decreased 
restenosis and reintervention rates compared to bare metal stents (BMS) (Hill et al 
2004; Mauri et al 2005; Roiron et al 2006). There is heterogeneity between outcomes 
depending on different drug coatings (sirolimus and its derivates versus paclitaxel and 
its derivates), suggesting higher efﬁ  cacy with sirolimus-eluting stents. This manuscript 
reviews the literature for the available applications of DES in the management of 
PAOD and presents recommendations for future treatment strategies.
Methods
We reviewed publications listed in MEDLINE that presented applications of DES in 
noncoronary arterial disease from 1950 up to March 2007. The key word searched was 
“stent” combined with terms describing stent coating, “eluting, paclitaxel, sirolimus”, and 
lesion location, “peripheral, infrapopliteal, below-the-knee, crural, femoral, iliac, renal, 
carotid, intravascular, extravascular”. In addition, relevant abstracts and presentations 
from pertinent conferences (TCT, CIRSE, Charing Cross and Euro-PCR) were identiﬁ  ed 
and the reference sections of retrieved articles were manually screened. Furthermore, 
ongoing unpublished trials were identiﬁ  ed by accessing www.clinicaltrials.gov.
Results
Drug-eluting stents have been used to ameliorate outcomes in the treatment of ath-
erosclerotic occlusive disease in various noncoronary locations. We believe that DES Vascular Health and Risk Management 2008:4(3) 554
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may inﬂ  uence outcomes depending on the vascular bed 
treated, thus, below are presented results subdivided into 
anatomic regions.
Lower limb arteries
Femoropopliteal vasculature
The investigators of the SIROCCO trial (SIROlimus Coated 
COrdis Self-expandable Stent), were the ﬁ  rst to publish the 
outcomes following use of sirolimus-eluting (SES) stents in 
the infrainguinal vasculature. This double-blind RCT evalu-
ated the efﬁ  cacy of sirolimus-eluting self-expanding nitinol 
stents versus the same commercially available bare metal 
stents (SMART®, Cordis. Miami, FL, USA) in the super-
ﬁ  cial femoral artery (SFA) (Duda et al 2002, 2005, 2006). 
The study was performed in 2 phases. After interim analysis 
of SIROCCO I revealed a high fracture rate, it was decided 
to reduce the maximal allowed lesion length from 20 cm to 
14.5 cm in order to decrease the number of stents implanted 
from 3 to 2 in an attempt to avoid stent fractures (Duda et al 
2002). In total, 93 patients with occlusions or stenoses (aver-
age lesion length 8.3 cm) at the level of the SFA were included. 
The sirolimus-eluting SMART® stent was implanted in 47 and 
the bare SMART® nitinol stent in 46 patients. (Duda et al 
2006) Both groups were followed for a mean of 24 months 
and no signiﬁ  cant differences were observed in either the 
peak velocity ratios (PVR), nor ankle-brachial index (ABI). 
At 24 months, the in-stent restenosis rate as measured by 
duplex ultrasound was not signiﬁ  cantly different between 
the sirolimus and the bare metal stent group, being 22.9% 
versus 21.1%, respectively. The target lesion revasculariza-
tion (TLR) was 6% in the sirolimus group and 13% in the 
bare stent group. Higher values were found for target vessel 
revascularization (TVR): 13% and 22%, respectively. (Duda 
et al 2006) In both groups at 24 months, no amputations were 
performed as a result of complications from stenting. The 
SIROCCO-investigators concluded that the study provided 
objective evidence supporting the safety and efﬁ  cacy of drug-
eluting and bare metal self-expanding nitinol SMART® stents 
in patients with chronic limb ischemia (CLI) and TASC C 
SFA lesions. They stated that no signiﬁ  cant difference could 
be found between the bare and the sirolimus-eluting SMART® 
stents, because the restenosis rate in the bare stent group was 
unexpectedly low (Duda et al 2002, 2005, 2006).
To date, SIROCCO is the only completed RCT that has 
published results showing the utility of DES in the femoro-
popliteal (FP) vasculature. At the preparation of this manu-
script, 2 further clinical trials investigating the efﬁ  cacy of 
different types of DES for the treatment of FP atherosclerotic 
occlusive disease are in the process of completing patient 
enrollment. It is hoped that publication of these ongoing 
trials will clarify whether DES are in fact superior to bare 
metal stents (BMS) in the FP area.
The ﬁ  rst trial from Abbott Vascular Inc (Santa Clara, CA, 
USA) has completed enrollment of 100 patients. Known as 
the STRIDES trial (SFA Treatment with Drug-Eluting Stents 
Study), this is a European prospective non-randomized con-
trolled trial that aims to evaluate the safety and performance 
of the DYNALINK-E® Everolimus-Eluting Peripheral Stent 
System in above-knee (AK) FP de novo or restenotic lesions. 
The maximal length of lesion treated is 17 cm. The second 
trial, the ZILVER® PTX™ paclitaxel-eluting stent study from 
Cook Inc (Bloomington, IN, USA) is also completing enroll-
ment. In this study, the safety and efﬁ  cacy of the ZILVER® 
PTX™ stent is being evaluated in the AK FP vasculature for 
lesions up to 28 cm in length. This study has 2 components, 
the ﬁ  rst being a randomized investigational device exemption 
(IDE) trial that compares 240 ZILVER® PTX™ patients with 
240 control patients. The control patients undergo percutane-
ous transluminal angioplasty (PTA) followed by placement of 
ZILVER® BMS for procedural failures. The second phase is 
a Global Registry evaluating an extra 760 ZILVER® PTX™, 
thus, giving a total of 1000 patients who will have received 
the paclitaxel-coated ZILVER® stents for FP lesions. At the 
2007 International Symposium on Endovascular Therapies 
(ISET) meeting in Miami (http://www.iset.org/), Michael 
Dake presented an interim report for the IDE-phase, on 
behalf of the ZILVER® PTX™ investigators. Data on the ﬁ  rst 
60 patients enrolled in the trial were presented. Twenty-eight 
patients were assigned to the ZILVER® PTX™ group and 32 
to the PTA control group. The mean follow-up duration was 
9 months (range 6–18 months). Based on this preliminary 
data set, Dake concluded that the use of DES in AK FP 
lesions did not result in any safety concerns. The event-free 
survival was 89% in the ZILVER® PTX™ versus 91% in 
the PTA groups. Stent safety at 6 months was evaluated by 
plain X-ray, which showed no stent fractures in any of the 
implanted stents, and IVUS which did not reveal aneurysm 
formation or strut malapposition. Taking into account acute 
treatment failure, the investigators found a higher 9-month 
primary patency rate in the patients assigned to the ZILVER® 
PTX™ treatment (90%) in comparison to the PTA control 
group (52%). Stent effectiveness as evaluated by prelimi-
nary results in this analysis leads us to anticipate an equally 
encouraging ﬁ  nal trial outcome.
These 2 landmark DES trials are of utmost importance for 
the endovascular community because positive results could Vascular Health and Risk Management 2008:4(3) 555
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facilitate implementation of broad changes in the treatment 
paradigm of PAOD.
Infrapopliteal vasculature
The diameter similarities between infrapopliteal and coronary 
vessels make the use of DES in the BK vascular bed an intui-
tive application. Feiring and colleagues (2004) were the ﬁ  rst 
to demonstrate the safety and utility of using coronary DES 
in the tibial vessels and paved the way for a more widespread 
application of DES for treating infrapopliteal disease.
Based on the outcome of 4 independent investigator-
intiated studies, the sirolimus-eluting Cypher® stent (Cordis, 
Miami, FL, USA) have been CE-marked for the BK indica-
tion (Siablis et al 2005; Scheinert et al 2005; Bosiers et al 
2006; Commeau et al 2006). Our own study (Bosiers et al 
2006) evaluated the Cypher® stent for BK applications in 18 
CLI patients (Rutherford 4 and 5) resulted in a 6-month limb 
salvage rate of 94.4% with an angiographic late lumen loss 
of only 0.38 mm in the surviving patients. Commeau and 
colleagues (2006) used SES to treat 30 consecutive patients 
with CLI (Rutherford category 3–6) and a minimum of 2 
diseased infrapopliteal vessels. A limb salvage rate of 100% 
was achieved at a mean follow-up of 7.7 months, and all 
surviving patients treated with Cypher® stents had marked 
clinical improvement with 97% primary patency as measured 
by target lesion revascularization (Commeau et al 2006). 
Siablis and colleagues (2005) compared the outcome of 29 
CLI patients treated with the sirolimus-eluting Cypher® stent 
with another 29 CLI patients receiving a BMS for infrapop-
liteal revascularization. The 6-month primary patency rate 
was signiﬁ  cantly higher in the Cypher® group compared to 
the BMS group (92.0% and 68.1%, respectively, p  0.002) 
(Siablis et al 2005). Angiographic follow-up 6-months post 
index intervention revealed a binary in-stent restenosis of 
only 4.0% after Cypher® stent implantation, while the rate 
was as high as 55.3% after BMS implantion (p  0.001) 
(Siablis et al 2005). Siablis and colleagues (2007) also 
published their one-year follow-up results showing 86.4% 
primary patency in patients with DES, whereas patients with 
BMS had primary patency of 40.5% (p  0.001). Likewise, 
the binary in-stent restenosis was better with DES, 36.7% 
in the Cypher® stent group, and 78.6% in the BMS group 
(p  0.001). (Siablis et al 2007). The same highly signiﬁ  cant 
difference in 6-month angiographic outcome between the 
Cypher® and the nondrug-eluting BX Sonic® stent (Cordis, 
Miami, FL, USA) was conﬁ  rmed by Scheinert and colleagues 
(2006) in a nonrandomized controlled trial. The study evalu-
ated 60 consecutive patients presenting with infrapopliteal 
lesions. The binary restenosis rate was found to be 0% in the 
Cypher® arm and 56.5% in the control BMS arm (p  0.001) 
(Scheinert et al 2006).
Feiring and Wesolowski (2007) recently proposed a new 
technique for combining antegrade popliteal arterial access 
with tibial DES implantation in patients with occluded SFA 
occlusions. Five patients scheduled for BK amputations, 
successfully received overlapping infrapopliteal DES via this 
approach. After a mean follow-up period of 29 months, no 
deaths, no amputations, and no TLR were recorded. (Feiring 
and Wesolowski 2007).
The current generation DES used for BK interventions 
are balloon-expandable, which are known to be crushable. 
Stent crushing and fracturing may negatively inﬂ  uence 
stent performance and patient clinical outcome. To date, 
one case report of a fractured DES has been published 
(Scharzmaier-D’Assie et al 2007). The development of 
small vessel drug-eluting, self-expanding nitinol stents 
may improve the efﬁ  cacy of the current generation of DES 
because self-expanding nitinol stents are less prone to frac-
tures when compared with balloon-expandable stents. This 
can be important if longer infrapopliteal lesions will start 
to be treated. Our group recently reported the 12-month 
results using the commercially available non-drug-eluting 
Xpert® (Abbott Vascular, Santa Clara, CA, USA) nitinol 
stent system in BK interventions. With a 12-month primary 
patency rate of 76.3%, and a limb salvage rate of 95.9%, 
the clinical outcome after bare metal nitinol stent implan-
tation was remarkable. Moreover, 12-month angiography 
with quantative vessel analysis (QVA) on the 73% of 
patients available for follow-up in the cohort revealed an 
angiographic binary restenosis rate of only 20.5%, which 
is comparable with well accepted coronary DES study 
outcomes. We attributed this optimal performance in the 
infrapopliteal arteries to the maintenance of ﬂ  ow dynamics 
because the stent was speciﬁ  cally designed for use in small 
vessels (Bosiers et al 2007). Although evidence currently 
indicates that the implantation of DES in the infrapopliteal 
vasculature leads to favorable outcomes with high mid-term 
primary patency and limb salvages rates, further support for 
the use of DES in patients with CLI and BK lesions will be 
gained from well-designed RCT. Such trials are about to 
start in conjunction with industry support.
Renal arteries
DES have also been applied for the treatment of renal artery 
stenosis, but as in the peripheral vascular bed, the number 
of publications remains sparse. Only 1 case report exists Vascular Health and Risk Management 2008:4(3) 556
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on the use of DES for bilateral renal stenting, Granillo 
and colleagues (2005) described a single case receiving a 
paclitaxel-eluting stent in both renal arteries. In another 
case report, Kakkar and colleagues (2006) reported on the 
implantation of a paclitaxel-eluting stent (Scimed®, Boston 
Scientiﬁ  c, Maple Grove, MN, USA) in a patient with recur-
rent renal artery in-stent restenosis. Angiographic control 
6 months after index intervention showed continued wide 
patency of the treated vessel (Kakkar et al 2006).
In an editorial comment, Zeller and colleagues (2006) 
described the potential role of DES in the treatment of renal 
artery stenosis. They made reference to the GREAT trial 
(Palmaz Genesis peripheral stainless steel balloon expand-
able stent: comparing a sirolimus-coated vs.a bare stent in 
REnal Artery Treatment), the only trial which evaluates the 
efﬁ  cacy of DES in renal artery disease. In this nonrandom-
ized, nonblinded, prospective, multicenter observational 
study, the sirolimus-eluting Palmaz Genesis™ Peripheral 
Stent (Cordis, Miami, FL) is compared with its bare metal 
counterpart in 105 consecutive, patients with symptomatic 
renal artery disease. Sapoval and colleagues (2005) published 
beneﬁ  cial results for the BMS arm of the study. Zähringer 
and colleagues (2007) published results from both arms of 
the study after 2 years of clinical follow-up. They reported 
that implantation of the sirolimus-eluting version led to 
an absolute reduction in the 6-month angiographic binary 
restenosis rate of 50% (BMS = 14.3%, DES = 6.7%; 
p = 0.30) After 1 year, the target lesion revascularization 
rate was 11.5% in the BMS group compared with 1.9% in 
the drug-eluting group (p = 0.21). Implantation of both BMS 
and DES led to signiﬁ  cant improvements in blood pressure, 
but 4%–7% patients had deterioration in renal function as 
measured by changes in serum creatinine. Despite, a trend 
toward improved outcome with DES in renal vasculature, 
the authors stated that the small sample size (n = 53) did 
not allow for detection of statistical signiﬁ  cance between 
groups. Zeller and colleagues (2006) conclude that DES 
might be beneﬁ  cial for patients with small renal arteries 
and impaired renal function. They believe that conventional 
BMS stent technology may lead to further deterioration in 
renal function because the need for reintervention exposes 
patients to recurrent administration of contrast and potential 
risk of renal embolism. According to their commentary, 
DES do not need to be used in patients with renal artery 
diameters greater or equal to 6 mm because results of exist-
ing endovascular interventions are already associated with 
a low restenosis rate in renal vasculature of this size. They 
state that use of DES may be preferable in patients with 
small diameter renal vessels (5 mm), a single, functional 
kidney or bilateral renal artery stenosis with small vessels, 
where the tendency toward inferior outcomes may justify 
the added expense and the risk of intensiﬁ  ed, prolonged 
antiplatelet therapy with acetylsalicylic acid and clopidogrel 
(Zeller et al 2006).
Supra-aortic arteries
Extracranial vasculature
Gupta and colleagues (2006) reported outcomes of DES in 
the extracranial circulation. They retrospectively reviewed 
data from 59 patients with either extra- (n = 36) or intracra-
nial stenoses (n = 29) treated with Cypher® or Taxus® stents. 
The majority of the extracranial stents were implanted in the 
vertebral artery (n = 31) or the internal carotid artery (ICA) 
(n = 5). Most (95%) procedures were technically success-
ful and the peri-procedural complication rate was 3% (one 
nonﬂ  ow limiting dissection and one stroke). Follow-up 
angiography (n = 41) or computed tomography (n = 7) per-
formed at a median of 4 months post implantation revealed 
a restenosis rate of 6% (Gupta et al 2006). Although these 
results are early and retrospective, they provide hope for 
patients with cerebrovascular atherosclerosis who have a 
19% risk of ipsilateral stroke when medically treated (Kasner 
et al 2006).
Two other authors have published case reports describing 
their experience with DES implanted for single extracranial 
lesions. Ko and colleagues (2004) mention in their report of 
25 extracranial vertebral artery stenosis treated with balloon-
expandable stents, the placement of one DES. At 1-month 
post-implantation, no adverse neurological events were 
observed (Ko et al 2004). In another case report Nussbaumer-
Ochsner and colleagues (2006) present a patient with pre-
procedural complaints of impaired left ocular perfusion and 
amaurosis fugax. The patient had occlusion at the origin of 
bilateral ICAs, stenoses of bilateral ECAs, and restenosis 
of the distal left CCA following prior endarterectomy. A 
Cypher® DES was implanted in the left ECA followed by 
placement of a non-drug-eluting self-expanding nitinol stent 
(Precise, Cordis. Miami, FL, USA) in the left CCA. The pro-
cedure was uneventful, and the ocular symptoms resolved. 
At 6 months, the patient remained asymptomatic, with both 
stents being angiographically patent (Nussbaumer-Oschner 
et al 2006).
Intracranial vasculature
Abou-Chebl and colleagues (2005) collected data from 
8 patients receiving a DES, 4 Cypher® and 4 Taxus® (Boston Vascular Health and Risk Management 2008:4(3) 557
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Scientiﬁ  c, Maple Grove, MN, USA). Stents were placed in 
the following locations: 3 intracranial ICA, 2 middle cerebral, 
2 basilar, and 1 vertebral artery stenosis. Patients had a 
signiﬁ  cant reduction in the initial stenosis (84% to 2.5%). 
One patient had a retinal embolism during guide catheter 
removal and there was a post-stenting, nonﬂ  ow-limiting, 
asymptomatic basilar artery dissection, which healed spon-
taneously during the follow-up period. No recurrence of 
cerebral ischemic events was observed during the follow-up 
period (mean 11.1 months). None of the angiographically 
studied patients (n = 5 of 8) developed signiﬁ  cant restenosis, 
and none required target vessel revascularization (Abou-
Chebl et al 2005).
In their retrospective analysis of patients treated with 
DES for both extra- and intracranial lesions, Gupta and col-
leagues (2006) described 29 intracranial cases treated with 
either Cypher® or Taxus® stents. In 19 cases, the lesions 
were in the intracranial vertebral or basilar artery, while the 
remaining 10 were in the intracranial ICA. Technically suc-
cessful stent implantation was achieved in 90% (26/29) of 
cases: the stent could not be deployed in 2 intracranial ICAs 
and 1 vertebral. Two peri-procedural complications were 
observed: 1 non-ﬂ  ow limiting dissection in an intracranial 
ICA and 1 disabling stroke 12 hours after placement of a 
basilar artery stent. There were no new restenotic lesions seen 
in 20 stents that were followed with repeat angiography or 
computed tomography at least 3 months after implantation 
(Gupta et al 2006).
Qureshi and colleagues (2006) retrospectively analysed 
18 patients stented with DES for symptomatic lesions located 
in the intracranial ICA (6), the proximal middle cerebral 
artery (4), the vertebral artery (4), the vertebrobasilar junc-
tion (2), or the basilar artery (2). A Cypher® stent was used 
in 14 cases and the remaining 4 received Taxus® stents. It 
was attempted to perform stenting in 3 more patients, but the 
procedure was unsuccessful, resulting in technical success 
rate of 85.7%. During the ﬁ  rst month after the intervention, 
no patients died and 1 patient experienced a major stroke. 
Cerebral angiography was performed in 7 patients at 6 
months follow-up and revealed a binary restenosis rate of 
14% (Qureshi et al 2006).
In our service, we performed a single Cypher® DES 
implantation in a 63-years old female patient presenting with 
a symptomatic high-grade stenosis situated in the intracranial 
segment of the ICA. Primary stenting was performed using 
a 3.5 mm diameter stent of 33 mm in length. The procedure 
was successfully completed without residual stenosis, or 
clinical complaints. To date, 2 years after the intervention, 
the patient is alive and has not experienced any further 
neurological events.
Discussion
At present, DES exist only on a balloon-mounted platform, 
which is expensive and potentially prone to crush injury. 
The expected superiority of DES for infrapopliteal and 
intracranial interventions in comparison to BMS is theoreti-
cal at present and extrapolated from outcomes seen in the 
coronary literature (Holmes et al 2004; Stone et al 2004). 
The need for performance of randomized controlled trials 
cannot be emphasized enough. The treatment of CLI, is 
one indication where use of DES may have a major impact. 
If treated strictly medically, only 50% of the patients with 
CLI will be alive without a major amputation after 1 year. 
Approximately 25% will have died and 25% will have had 
a major amputation (Norgren et al 2007; Siablis et al 2007). 
These patients lack conduit, have unsuitable target vessels 
for revascularization and signiﬁ  cant comorbidities that pre-
clude open surgical intervention. The paradigm has shifted 
to minimally invasive revascularization using PTA and stent-
ing, but, although this approach has modiﬁ  ed outcomes, the 
present 30%–50% restenosis rate at one year after PTA and 
implantation of BMS in the below-knee location warrants 
further improvement (Siablis et al 2005; Scheinert et al 2005; 
Commeau et al 2006).
There is also deﬁ  nitely room for improvement in the 
intracranial circulation. The compelling stroke rate seen in the 
WASID study, where patients with greater than 70% intra-
cranial stenosis treated medically had a 23% stroke rate at 
one year, and, the 35% documented angiographic restenosis 
seen in the SSYLVIA trial, where the bare metal, balloon-
expandable Neurolink® stent (Advanced Cardiovascular Inc., 
Guidant, Indianapolis, IN) was implanted, both highlight 
the limitations of existing treatment strategies (SSYLVIA 
Investigators 2004; Chimowitz et al 2005). Despite the high 
angiographic restenosis rate seen after BMS implantion 
in the SSYLVIA trial, only 40% of these restenosis led to 
neurologic complaints. It is therefore unclear, whether the 
potential for symptomatic restenosis reduction that might 
be provided with DES implants in this location outweighs 
the risk of early thombotic occlusion attributed to DES.
The initial enthusiasm for DES stems from their efﬁ  cacy 
in reducing in-stent restenosis and neointimal hyperplasia 
from 30% to approximately 5% (Holmes et al 2004; Stone 
et al 2004). Although direct arterial toxicity from the eluted 
drugs is unfounded, there are late thromboses secondary 
to delayed endothelialization that necessitate prolonged Vascular Health and Risk Management 2008:4(3) 558
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dual antiplatelet therapy and should temper nonchalant 
use of DES (Levy et al 2004; Moreno et al 2005). Unlike 
in animal models, use of DES in human atherosclerotic 
arteries results in delayed endothelialazation around the 
stent struts and thus makes the stent more susceptible to 
thrombosis. In coronary DES trials, the increased incidence 
of thrombosis with DES is small, in the order of 0.6% per 
annum, but, the accompanying 31%–45% mortality rate 
from the resultant myocardial infarction is of great concern 
(Harper 2004). Despite the fact that DES thrombosis in the 
peripheral circulation is not as lethal as in coronaries, dual 
antiplatelet therapy after DES is also warranted for PAOD 
to guarantee optimal stent performance and patient clinical 
well-being. Nevertheless, the use of dual antiplatelet therapy 
is related with an increased incidence (1%–2% per annum) 
of major bleeding complications and is expensive (Diener 
et al 2004; Eisenstein et al 2007). One year of clopidogrel 
costs approximately US$1000.00. This expense is in addi-
tion to the cost already incurred by using a DES, which is 
usually fourfold greater than the bare metal equivalent; one 
coronary BMS costs US$800.00 while one DES costs up to 
US$2500.00 (Harper 2004). The duration of treatment with 
dual antiplatelet therapy after both coronary and peripheral 
implantation of DES remains a subject of ongoing debate. 
Based on emerging evidence, many cardiologists are recom-
mending a minimum of 12 months of aspirin and clopidogrel, 
but, some are advocating indeﬁ  nite use of dual antiplatelet 
therapy after DES implantation (Waksman 2006).
To overcome some of the shortcomings of the current gen-
eration of DES, further modiﬁ  cations in already existing stent 
technology need to be pursued, especially for infrapopliteal 
interventions. As CLI patients most often present with long, 
diffuse BK lesions, longer stents need to be manufactured to 
make use of DES more cost-effective in the BK vasculature. 
Especially for these longer lesions, there might be need for 
the development of speciﬁ  c infrapopliteal, drug-eluting, 
self-expanding nitinol stents to help circumvent potential 
crushing and strut fractures seen with the balloon-expandable 
platform (Scharzmaier-D’Assie et al 2007). One option 
involves development of drug-eluting bioabsorbable stents 
(Waksman 2006). The limitation of bioabsorbable stents has 
been the inﬂ  ammatory response that is elicited after implan-
tation. Modiﬁ  cation of this response through local elution of 
anti-inﬂ  ammatory, antiproliferative drugs should minimize 
restenosis, as well as inhibit injury-induced neointimal hyper-
plasia. As the requirement for vessel scaffolding provided 
by the stent is only needed temporarily, subsequent absorp-
tion of the stent should, in turn, allow endothelialazation, 
thus, precluding the need for ongoing antiplatelet therapy. 
(Waksman 2006) Another approach involves development of 
stents with inherent antithrombotic properties, such as stents 
coated with monoclonal antibodies capable of capturing cir-
culating endothelial progenitor cells. (Harper 2004).
Conclusion
At present, the use of DES for noncoronary applications is 
investigational. Although there are good indications and 
some publications supporting the use of DES in several 
noncoronary vascular beds, more data and long-term follow-
up are needed. The results from nonrandomized, controlled 
trials such as the ZILVER® PTX™ and STRIDES trials are 
eagerly anticipated, but, ultimately, randomized controlled 
trials comparing DES with BMS implantation need to be 
performed to determine DES superiority. Until these results 
are available, review of the literature prompts us to make the 
following recommendations:
1.  DES in the SFA provide no added beneﬁ  t to the current 
generation of nitinol BMS, except, in complex lesions 
(long stenoses or occlusions). Additionally, in these type of 
complex lesions it will need to be investigated whether the 
potential improved patency and quality adjusted life year 
(QALY), outweigh the increased cost of (multiple) DES 
and the need for prolonged dual-antiplatelet therapy.
2.  DES in the infrapopliteal vasculature of patients with 
CLI have the greatest potential beneﬁ  t because the one-
year restenosis after implantation of BMS stents in this 
location is high (50%) (Bosiers et al 2006). From a ﬁ  nan-
cial standpoint, there is existing coronary drug-eluting 
technology that can also be used in the infrapopliteal 
vasculature thus making this a more cost-effective under-
taking. Preliminary results using DES in the infrapopliteal 
vasculature from single center studies are encouraging 
with low amputation rates (5% vs 50% for untreated 
patients with CLI) (Siablis et al 2005; Bosiers et al 2006; 
Commeau et al 2006). There is need for RCTs and there 
are plans to perform these in conjuction with industry.
3.  DES in renal interventions provides no added beneﬁ  t to the 
current generation of balloon-expandable stents, except 
potentially in patients with solitary functional kidneys, 
where treatment failure has more compelling implica-
tions, or in patients with small renal arteries (5 mm) 
where outcomes are less favourable. Conﬁ  rmation with 
RCTs is required.
4.  Due to lack of evidence, DES in the intracranial and 
extracranial cerebrovascular vasculature is currently not 
supported.Vascular Health and Risk Management 2008:4(3) 559
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